By Joe Hoppe

 

Sensyne Health PLC said Friday that it has signed a research collaboration agreement for an undisclosed amount with Bristol Myers Squibb, applying its technology to conduct research into rare blood diseases.

The U.K. clinical-technology company said the collaboration will initially focus on applying its machine-learning technology to research disease progression and patient stratification for patients within the Myeloproliferative Neoplasms group of rare blood diseases. Patients within this group have diseases characterized by the overproduction of one or more types of blood cells.

Sensyne said the collaboration will be its fourth successive partnership with a major pharmaceutical company, following collaborations signed with Bayer AG, Roche Holding AG and Alexion Pharmaceuticals Inc.

"As we continue to see wider adoption of clinical artifical intelligence and machine learning by the life sciences industry to support pharmaceutical research, Sensyne is ideally positioned to help accelerate the discovery and development of new medicines for patients," said Chief Executive Paul Drayson.

Shares at 0739 GMT were up 7 pence, or 8%, at 99.5 pence.

 

Write to Joe Hoppe at joseph.hoppe@wsj.com

 

(END) Dow Jones Newswires

October 23, 2020 03:57 ET (07:57 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Bristol Myers Squibb Charts.